101 related articles for article (PubMed ID: 19998574)
1. Government regulation of pricing and reimbursement of prescription medicines: results of a recent multi-country review.
Kingham R; Wheeler J
Food Drug Law J; 2009; 64(1):101-14. PubMed ID: 19998574
[TBL] [Abstract][Full Text] [Related]
2. Economic Evaluation for Pricing and Reimbursement of New Drugs in Spain: Fable or Desideratum?
Oliva-Moreno J; Puig-Junoy J; Trapero-Bertran M; Epstein D; Pinyol C; Sacristán JA
Value Health; 2020 Jan; 23(1):25-31. PubMed ID: 31952669
[TBL] [Abstract][Full Text] [Related]
3. Societal perspective on access to publicly subsidised medicines: A cross sectional survey of 3080 adults in Australia.
Chim L; Salkeld G; Kelly P; Lipworth W; Hughes DA; Stockler MR
PLoS One; 2017; 12(3):e0172971. PubMed ID: 28249013
[TBL] [Abstract][Full Text] [Related]
4. Pharmaceutical pricing and reimbursement policies in Algeria, Morocco, and Tunisia: comparative analysis.
Dahmani H; Fradi I; Achour L; Toumi M;
J Mark Access Health Policy; 2023; 11(1):2244304. PubMed ID: 37614557
[TBL] [Abstract][Full Text] [Related]
5. A Review of the Evidence on Attitudes, Perceived Impacts and Motivational Factors for European Member State Collaboration for Pricing and Reimbursement of Medicines: Time for the EEA Member States to Apply Their Experience and Expertise in Evidence-Based Decision Making to Their Current Pharmaceutical Policy Challenges.
Vella Bonanno P; Cassar V; Godman B
Front Pharmacol; 2021; 12():666405. PubMed ID: 34867312
[TBL] [Abstract][Full Text] [Related]
6. International variability in the reimbursement of cancer drugs by publically funded drug programs.
Cheema PK; Gavura S; Migus M; Godman B; Yeung L; Trudeau ME
Curr Oncol; 2012 Jun; 19(3):e165-76. PubMed ID: 22670106
[TBL] [Abstract][Full Text] [Related]
7. Comparison of pharmaceutical pricing and reimbursement systems in Turkey and certain EU countries.
Atikeler EK; Özçelikay G
Springerplus; 2016; 5(1):1876. PubMed ID: 27833835
[TBL] [Abstract][Full Text] [Related]
8. An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a Reference Country for the Middle-Income European Countries.
Kamusheva M; Vassileva M; Savova A; Manova M; Petrova G
Front Public Health; 2018; 6():61. PubMed ID: 29556491
[TBL] [Abstract][Full Text] [Related]
9. Digital Health Reimbursement Strategies of 8 European Countries and Israel: Scoping Review and Policy Mapping.
van Kessel R; Srivastava D; Kyriopoulos I; Monti G; Novillo-Ortiz D; Milman R; Zhang-Czabanowski WW; Nasi G; Stern AD; Wharton G; Mossialos E
JMIR Mhealth Uhealth; 2023 Sep; 11():e49003. PubMed ID: 37773610
[TBL] [Abstract][Full Text] [Related]
10. The challenges of access to innovative medicines with limited evidence in the European Union.
Vallano A; Pontes C; Agustí A
Front Pharmacol; 2023; 14():1215431. PubMed ID: 37719853
[TBL] [Abstract][Full Text] [Related]
11. Pediatric Market Access: A Qualitative Study.
Maas L; Joos A; Hiligsmann M
Ther Innov Regul Sci; 2024 Mar; 58(2):336-346. PubMed ID: 38172379
[TBL] [Abstract][Full Text] [Related]
12. Access to innovative drugs and the National Reimbursement Drug List in China: Changing dynamics and future trends in pricing and reimbursement.
Macabeo B; Wilson L; Xuan J; Guo R; Atanasov P; Zheng L; François C; Laramée P
J Mark Access Health Policy; 2023; 11(1):2218633. PubMed ID: 37325810
[TBL] [Abstract][Full Text] [Related]
13. Differences in time to patient access to innovative cancer medicines in six European countries.
Vancoppenolle JM; Franzen N; Koole SN; Retèl VP; van Harten WH
Int J Cancer; 2024 Mar; 154(5):886-894. PubMed ID: 37864395
[TBL] [Abstract][Full Text] [Related]
14. Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia.
Wasir R; Irawati S; Makady A; Postma M; Goettsch W; Buskens E; Feenstra T
PLoS One; 2019; 14(2):e0212328. PubMed ID: 30779809
[TBL] [Abstract][Full Text] [Related]
15. Assessing the impact of the Australia-United States Free Trade Agreement on Australian and global medicines policy.
Faunce T; Doran E; Henry D; Drahos P; Searles A; Pekarsky B; Neville W
Global Health; 2005 Oct; 1():15. PubMed ID: 16209703
[TBL] [Abstract][Full Text] [Related]
16. Patient organisations and the reimbursement process for medicines: an exploratory study in eight European countries.
Noordman J; van Dijk L; Friele R
BMC Health Serv Res; 2010 Feb; 10():45. PubMed ID: 20170557
[TBL] [Abstract][Full Text] [Related]
17. Impact of the European Union on access to medicines in low- and middle-income countries: A scoping review.
Perehudoff K; Durán C; Demchenko I; Mazzanti V; Parwani P; Suleman F; de Ruijter A
Lancet Reg Health Eur; 2021 Oct; 9():100219. PubMed ID: 34693391
[TBL] [Abstract][Full Text] [Related]
18. Role of centralized review processes for making reimbursement decisions on new health technologies in Europe.
Stafinski T; Menon D; Davis C; McCabe C
Clinicoecon Outcomes Res; 2011; 3():117-86. PubMed ID: 22046102
[TBL] [Abstract][Full Text] [Related]
19. [TOPICAL ISSUES OF FUNCTIONING AND DEVELOPMENT OF THE SINGLE MARKET OF MEDICINES OF THE EURASIAN ECONOMIC UNION].
Tonkonog VV; Ananchenkova PI; Shimanovskyi NL; Vrubel ME
Probl Sotsialnoi Gig Zdravookhranenniiai Istor Med; 2023 Oct; 31(Special Issue 2):1268-1274. PubMed ID: 38069897
[TBL] [Abstract][Full Text] [Related]
20. European priority review vouchers for neglected disease product development.
Ridley DB; Lasanta AM; Storer Jones F; Ridley SK
BMJ Glob Health; 2024 Jan; 9(1):. PubMed ID: 38290786
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
